Media coverage about pSivida Corp. (NASDAQ:PSDV) has been trending somewhat positive on Wednesday, according to Accern Sentiment. Accern scores the sentiment of press coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. pSivida Corp. earned a media sentiment score of 0.14 on Accern’s scale. Accern also gave media headlines about the company an impact score of 46.5106264262606 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.

Here are some of the media headlines that may have impacted Accern’s rankings:

Several equities analysts have weighed in on PSDV shares. Ladenburg Thalmann Financial Services set a $13.00 target price on shares of pSivida Corp. and gave the company a “buy” rating in a report on Wednesday, June 14th. HC Wainwright restated a “buy” rating and set a $5.00 target price on shares of pSivida Corp. in a report on Tuesday. Rodman & Renshaw started coverage on shares of pSivida Corp. in a report on Tuesday, May 30th. They set a “buy” rating and a $8.00 target price for the company. FBR & Co restated a “buy” rating on shares of pSivida Corp. in a report on Wednesday, June 14th. Finally, Northland Securities set a $10.00 target price on shares of pSivida Corp. and gave the company a “buy” rating in a report on Wednesday, June 14th. Five research analysts have rated the stock with a buy rating, The company presently has a consensus rating of “Buy” and a consensus price target of $8.60.

pSivida Corp. (PSDV) traded down 3.08% during midday trading on Wednesday, hitting $1.26. 292,802 shares of the company’s stock traded hands. pSivida Corp. has a 52 week low of $1.03 and a 52 week high of $3.82. The company’s market capitalization is $48.73 million. The company has a 50 day moving average of $1.19 and a 200-day moving average of $1.65.

pSivida Corp. (NASDAQ:PSDV) last issued its quarterly earnings results on Monday, September 11th. The company reported ($0.16) EPS for the quarter, hitting the consensus estimate of ($0.16). pSivida Corp. had a negative net margin of 245.19% and a negative return on equity of 132.95%. The firm had revenue of $0.70 million for the quarter, compared to analysts’ expectations of $0.48 million. Equities research analysts predict that pSivida Corp. will post ($0.56) earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: “Somewhat Favorable News Coverage Somewhat Unlikely to Impact pSivida Corp. (PSDV) Stock Price” was reported by Daily Political and is the property of of Daily Political. If you are reading this report on another website, it was copied illegally and reposted in violation of US and international copyright legislation. The correct version of this report can be accessed at

pSivida Corp. Company Profile

pSivida Corp. develops drug delivery products primarily for the treatment of chronic eye diseases. The Company operates through the biotechnology sector segment. The Company has developed three products for treatment of back-of-the-eye diseases, which include Medidur for posterior segment uveitis, its lead product candidate that is in pivotal Phase III clinical trials; ILUVIEN for diabetic macular edema (DME), its lead licensed product that is sold in the United States and European Union (EU) countries, and Retisert.

Insider Buying and Selling by Quarter for pSivida Corp. (NASDAQ:PSDV)

Receive News & Ratings for pSivida Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for pSivida Corp. and related companies with's FREE daily email newsletter.